Taxane-based treatment regimens are standard first-line therapies for metastatic breast cancer (MBC). The clinical benefit of solvent-based taxanes, including solvent-based paclitaxel and docetaxel, in MBC has been established in large randomized clinical trials. Docetaxel has demonstrated greater efficacy versus solvent-based paclitaxel in at least one trial, but both solvent-based paclitaxel and docetaxel are associated with undesirable dose-limiting toxicities, including neutropenia, sensory neuropathy, and hypersensitivity reactions. nab-Paclitaxel, an albuminbound form of paclitaxel, was developed to improve the therapeutic index of taxane treatment. This review summarizes preclinical experiments and clinical data from MBC trials comparing nab-paclitaxel with docetaxel. In preclinical studies, nab-paclitaxel more effectively suppressed tumor growth than docetaxel (80 versus 29 % inhibition) in breast cancer tumor xenograft models and was associated with less toxicity. Clinical studies confirmed these findings and reported a better therapeutic index with nab-paclitaxel than docetaxel. As such, the clinical experience with nabpaclitaxel supports its role as an important advance in the treatment of MBC with taxane-based regimens.
A meta-analysis of randomized trials in MBC comparing taxane-containing therapies versus nontaxane-containing therapies revealed a statistically significant longer overall survival (OS) among patients receiving taxane-containing regimens, supporting the key role that taxanes play in MBC treatment. 3 The potent anticancer activity of taxanes stems from their capacity to inhibit microtubule dynamics by binding directly to b-tubulin subunits (see Figure 1 ). In doing so, taxanes promote microtubule polymerization, inhibit microtubule depolymerization, and enhance microtubule stability. 4, 5 When taxanes bind to microtubules, these normally dynamic structures form highly organized microtubule bundles and become dysfunctional.
Consequently, taxanes induce cell death by disrupting mitotic spindle formation during the G2 and M phases of the cell cycle. 4, 6 Despite sharing this similar mechanism of action, the formulations of solvent-based paclitaxel, docetaxel and nab-paclitaxel differ; this may explain some of the differences in their efficacy and safety profiles.
This article describes the clinical experience to date with solvent-based taxanes from large pivotal phase III trials of patients with MBC with a particular emphasis on the toxicity challenges associated with these agents. The rationale for the development of nab-paclitaxel and its unique mechanism of delivery are also described. Finally, preclinical and clinical studies of nab-paclitaxel and docetaxel in MBC are reviewed.
History of Taxane Development Solvent-based Paclitaxel
Paclitaxel was discovered as a result of a large-scale effort by the National Cancer Institute to identify plant extracts with antitumor properties in the 1960s. 5 In a landmark publication in 1971, Wani et al.
described paclitaxel being isolated from the bark of the Taxus brevifolia tree and initial preclinical studies that revealed its potent preclinical anticancer activity. 7 As paclitaxel is extremely hydrophobic, it is difficult to solubilize. Its insolubility, together with the potential difficulties in harvesting a limited natural resource, nearly thwarted the clinical development of paclitaxel. 5, 8 Eventually, Cremophor® EL (CrEL), a polyoxyethylated castor oil, combined with dehydrated alcohol, United States Pharmacopeia (USP), emerged as a promising vehicle for paclitaxel delivery and remains in the formulation of solvent-based paclitaxel available commercially. 8, 9 © TOUCH MEDICAL MEDIA 2013 DOI: 10 .17925/OHR.2013.09. 1.45 It was reported in early trials of solvent-based paclitaxel that the taxanes had similar efficacy to anthracyclines, the standard of care for MBC at the time. Compared with anthracyclines in the first-line setting, solvent-based paclitaxel at its now indicated dose (175 mg/m 2 via a 3 hour intravenous infusion every 3 weeks) and doxorubicin elicited mostly similar efficacy outcomes, including OS. 10, 11 Given these findings, solvent-based paclitaxel was approved to treat previously untreated MBC in 1994. 12 Despite the promising clinical activity described above, it became clear that treatment with solvent-based paclitaxel exposed patients to peripheral neuropathy, hypersensitivity reactions, and neutropenia. 9, 13 Hypersensitivity reactions have been independently attributed to CrEL. 8, 14 The mechanism underlying CrEL-triggered hypersensitivity reactions is The most common toxicities associated with the weekly schedule have been reported to be neutropenia and neuropathy. 15 In addition to inducing hypersensitivity reactions and contributing to the risk for peripheral neuropathy in some patients, 8 CrEL also limits the pharmacokinetics of solvent-based paclitaxel. [17] [18] [19] [20] [21] When administered via a 3-hour intravenous infusion, solvent-based paclitaxel exhibits a nonlinear increase in systemic exposure with rising doses of drug. 17, 20, 21 Such disproportionate increases in paclitaxel exposure have been attributed to the capacity of CrEL to form micelles that encapsulate the active drug, as well as other drugs administered with it. [19] [20] [21] In doing so, CrEL reduces levels of paclitaxel available for cell partitioning and its rate of elimination. 19, 21 Consequently, CrEL limits the therapeutic index of solvent-based paclitaxel by nonselectively increasing the systemic exposure to paclitaxel. [17] [18] [19] [20] [21] Taken together, the toxicities and limiting pharmacokinetics of solvent-based paclitaxel leave room for additional therapies with improved efficacy and tolerability profiles.
Docetaxel
Docetaxel, a semisynthetic analog of paclitaxel, was developed in an effort to overcome the challenges associated with harvesting sufficient amounts of a natural resource for cancer research relative to the starting material originally required for paclitaxel. 4 Of paclitaxel analogs examined, docetaxel had the most promising antitumor activity, owing to its potent inhibition of microtubule dynamics. 22 Similar to paclitaxel, docetaxel is difficult to solubilize. Rather than using
CrEL as a vehicle though, docetaxel is formulated with polysorbate 80
(Tween® 80). Tween is similar to CrEL in that it is also thought to form micelle-like structures, which influence docetaxel pharmacokinetics. 8 In its Tween-based form, the FDA conditionally approved docetaxel in 1996
for patients with MBC who had progressed or relapsed after anthracyclinebased chemotherapy. 23 Similar to paclitaxel, docetaxel was compared with anthracyclines in its early clinical trials. TAX 304 is the pivotal phase III trial that led to its full approval in this setting. 12 A total of 392 patients with MBC progressing after anthracycline-based chemotherapy were randomized to either docetaxel at a dose of 100 mg/m 2 every 3 weeks or a combination regimen of mitomycin plus vinblastine, a salvage regimen that was widely used at the time the trial was designed. Thus, some gain in efficacy was offset with a higher degree of toxicity.
In an effort to examine whether alternative dosing schedules might improve the therapeutic index of docetaxel, a phase III study was conducted to compare the recommended every-3-week schedule versus weekly dosing in patients with MBC. 27 
nab-Paclitaxel
The toxicities associated with both solvent-based paclitaxel and docetaxel combined with the encouraging efficacy of both taxanes for the treatment of MBC brought about a desire to improve the therapeutic index of taxane therapy. nab-Paclitaxel was developed in an effort to meet this desire. 
Preclinical and Pharmacokinetic Studies
Preclinical studies helped elucidate the unique mechanism of delivery of nab-paclitaxel. In early mouse tumor xenograft models, nab-paclitaxel appeared to deliver higher concentrations of cytotoxin to tumors than solvent-based paclitaxel. 28 In doing so, it was less toxic to mice than solvent-based paclitaxel. Furthermore, increased antitumor activity was observed with nab-paclitaxel, as evidenced by its prolongation of time to recurrence and tumor doubling time, as well as decreased tumor volume after treatment.
28
Supporting the enhanced antitumor activity observed with nabpaclitaxel compared with solvent-based paclitaxel were findings from a pharmacokinetic study, which indicated that the disposition of paclitaxel depends on its formulation. 34 Fourteen patients received at least one cycle of solvent-based paclitaxel and one cycle of nab-paclitaxel. Although total drug exposure did not differ between the two formulations (p=0.72), exposure to unbound paclitaxel was significantly higher after nab-paclitaxel than after solvent-based paclitaxel. Higher systemic exposure was thought to be a function of the increased free drug fraction (0.063±0.021 versus 0.024±0.009; p<0.001), which likely drives drug uptake by malignant cells.
These findings may at least in part explain the preclinical finding of greater antitumor activity with nab-paclitaxel than solvent-based paclitaxel. 34 Research into the exact mechanism of delivery of nab-paclitaxel is ongoing;
however, it is hypothesized that nab-paclitaxel may take advantage of albumin-mediated transport to reach tumors. 35 Albumin crosses endothelial cell membranes by binding with high affinity to the 60 kDa glycoprotein (gp60) cell surface receptors, triggering caveolae formation, which is then followed by internalization of vesicles into endothelial cells. 36 vesicles cross the cells and fuse with the opposite membrane, releasing their contents into the subendothelial space. 36 Albumin-bound paclitaxel and free paclitaxel may also reach the subendothelial space by the enhanced permeation and retention (EPR) effect. 37, 38 In the case of tumors, the subendothelial space may represent the tumor interstitium. Once in the tumor interstitium, albumin-binding proteins, such as secreted protein acidic and rich in cysteine (SPARC), are hypothesized to retain albumin-bound paclitaxel in the tumor interstitial space. 29, 31, 32, 35, 39 It has been hypothesized that nabpaclitaxel may leverage the interaction between SPARC and albumin to accumulate in the tumor microenvironment (see Figure 2 ).
35
The antitumor activity and tolerability of nab-paclitaxel have been compared with those of docetaxel in preclinical studies using mouse xenograft models created by implanting athymic mice with breast cancer cells from human tumors. 29 For assessment of tumor growth or regression, tumor diameters and tumor volume over time were measured.
Suppression of tumor growth was defined as the percent decrease in tumor volume in treated versus control mice at the time of euthanasia. to patients who were exposed to anthracycline treatment. 24 Table 4 ), again underscoring the benefits of nabpaclitaxel over first-generation taxanes in MBC. 42 The most common treatment-emergent AEs reported with weekly nabpaclitaxel and every-3-week docetaxel noted after the initial analysis of the phase II trial were neutropenia, alopecia, neuropathy, fatigue, and arthralgia (see Table 5 ). 42 and 300 mg/m 2 every-3-week nab-paclitaxel arms, respectively, and 30 % in the docetaxel arm. 42 The treatment arm with the best AE profile proved to be weekly nab-paclitaxel 100 mg/m 2 , which had the lowest rates of grade 4 neutropenia and grade 3 sensory neuropathy and fatigue. Overall, the results of this study demonstrated that weekly schedules of nabpaclitaxel may have a better therapeutic index than docetaxel.
41,42

Discussion and Conclusions
Based on the preclinical studies and clinical trial data reviewed here, nab-paclitaxel represents a novel delivery platform for taxanes to reach tumors and preferentially accumulate near malignant cells. Because both docetaxel and nab-paclitaxel arose from efforts to improve on the therapeutic index of taxane treatment after solvent-based paclitaxel was developed, the comparison of these two agents is logical. nab-Paclitaxel appears to be better tolerated and more efficacious than docetaxel in the comparative data available to date. 41, 42 In addition, administration of nab-paclitaxel does not require any premedication for potential hypersensitivity reactions, making it the more convenient option for most patients.
23,33
nab-Paclitaxel demonstrated greater ORR, PFS, OS, and tolerability than docetaxel in patients with MBC. 41, 42 This trial suggested that weekly administration may be the ideal schedule for nab-paclitaxel. 41, 42 The 150 mg/m 2 weekly dose was associated with greater efficacy but also a higher rate of dose reductions due to toxicity versus the 100 mg/m 46 Overall, most
AEs were consistent with earlier trials that examined dose-dense AC followed by dose-dense solvent-based paclitaxel. However, most patients in the pilot study did not require prophylactic pegfilgrastim, whereas those in the trial with standard paclitaxel did. 46 Grade 2/3 peripheral neuropathy was common with nab-paclitaxel but resolved after the trial in most patients. 46 Based on these findings, the study authors concluded that dose-dense AC followed by dose-dense nab-paclitaxel is feasible in early-stage breast cancer. 46 A separate phase II study examined a similar regimen, albeit with the addition of bevacizumab, in early-stage breast cancer. 45 A total of 197 patients with early-stage breast cancer were randomized to receive dose dense AC followed by dose-dense nab-paclitaxel (260 mg/m 2 every 2 weeks plus bevacizumab or dose-dense AC followed by solvent-based paclitaxel (175 mg/m 2 every 2 weeks) plus bevacizumab. The majority of patients in both arms completed all four cycles of planned therapy. Compared with patients receiving solvent-based paclitaxel, those given nab-paclitaxel received 44% more of the study drug during the trial. Percentages of AC and bevacizumab received by each treatment arm did not significantly differ.
All study participants experienced at least one treatment-related AE, with the most common being fatigue, sensory neuropathy, leukopenia, anemia, nausea, and alopecia in both arms. Notably, no differences in grade ≥3
taxane-associated AEs were reported between treatment arms, suggesting that nab-paclitaxel is as feasible as solvent-based paclitaxel in this setting;
however, no efficacy values were reported in this study. 45 In conclusion, taxanes remain a cornerstone of MBC treatment. 
